A 12 MONTH CORE STUDY TO ASSESS THE EFFICACY AND SAFETY OF RANIBIZUMAB (INTRAVITREAL INJECTIONS) IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA AND A 24 MONTH OPEN-LABEL EXTENSION STUDY: